Hamad Raphael, Nguyen Anthony, Laliberté Éric, Bouchard Denis, Lamarche Yoan, El-Hamamsy Ismail, Demers Philippe
From the *Faculty of Medicine, University of Montreal, Montreal, QC Canada; and †Department of Cardiac Surgery, Montreal Heart Institute, Montreal, QC Canada.
Innovations (Phila). 2017 Sep/Oct;12(5):356-362. doi: 10.1097/IMI.0000000000000403.
del Nido solution (DNS) is a single-dose cardioplegia designed for pediatric use proposed to offer superior myocardial protection in adults. However, few data support this claim. We hypothesized that DNS and modified blood cardioplegia solution (BS) provide equivalent safety in combined adult valve surgery.
Between November 2014 and December 2015, 25 patients underwent primary aortic valve replacement and concomitant coronary artery bypass grafting (CABG) with DNS. Outcomes were compared with 25 patients who underwent the same surgery with BS between September 2013 and August 2015.
All preoperative characteristics, comorbidities, and number of CABG performed were similar between groups. One hospital death occurred in the BS group. Postoperative creatine kinase, MB isotype (16.7 ± 5.3 μg/L vs. 22.1 ± 8.9 μg/L, P = 0.011) and troponin T levels (260 ± 105.3 ng/L vs. 370.5 ± 218.4 ng/L, P = 0.028) were significantly lower in the DNS group. There was no difference in inotropic or vasoactive agent use (P = 0.512). Cardiopulmonary bypass times (65.5 ± 12.5 min vs. 76.6 ± 19.1 min, P = 0.019) and cross-clamp times (55.6 ± 11.2 min vs. 64.3 ± 18.9 min, P = 0.05) were lower in the DNS group but total operating room times (P = 0.198) were similar. Peak postoperative creatinine levels were similar in both groups (P = 0.063). There was no difference in postoperative outcomes including acute renal failure (P > 0.999), atrial fibrillation (P = 0.773), acute respiratory failure (P > 0.999), nor stroke or transient ischemic attack (P > 0.999). Intensive care unit stay (P = 0.213) and hospital stay (P = 0.1) did not differ between groups.
The DNS can be used as an alternative to BS in adult concomitant aortic valve replacement + CABG surgery. This supports our hypothesis that in this specific setting, DNS provides comparable myocardial protection as BS, with possibly shorter cardiopulmonary bypass and cross-clamp times.
del Nido溶液(DNS)是一种设计用于儿科的单剂量心脏停搏液,有人提出它能为成人提供更好的心肌保护。然而,几乎没有数据支持这一说法。我们假设在成人心脏瓣膜联合手术中,DNS和改良血液心脏停搏液(BS)具有同等安全性。
2014年11月至2015年12月期间,25例患者在接受主动脉瓣置换术同时行冠状动脉旁路移植术(CABG)时使用了DNS。将结果与2013年9月至2015年8月期间25例接受相同手术并使用BS的患者进行比较。
两组之间所有术前特征、合并症以及CABG的实施数量均相似。BS组发生1例医院死亡。DNS组术后肌酸激酶MB同工酶水平(16.7±5.3μg/L对22.1±8.9μg/L,P = 0.011)和肌钙蛋白T水平(260±105.3 ng/L对370.5±218.4 ng/L,P = 0.028)显著更低。在使用正性肌力药或血管活性药物方面无差异(P = 0.512)。DNS组的体外循环时间(65.5±12.5分钟对76.6±19.1分钟,P = 0.019)和主动脉阻断时间(55.6±11.2分钟对64.3±18.9分钟,P = 0.05)更低,但总手术室时间相似(P = 0.198)。两组术后肌酐峰值水平相似(P = 0.063)。术后包括急性肾衰竭(P>0.999)、心房颤动(P = 0.773)、急性呼吸衰竭(P>0.999)以及中风或短暂性脑缺血发作(P>0.999)等结果无差异。重症监护病房住院时间(P = 0.213)和住院时间(P = 0.1)在两组之间无差异。
在成人主动脉瓣置换术+CABG联合手术中,DNS可作为BS的替代方案。这支持了我们的假设,即在这种特定情况下,DNS与BS提供相当的心肌保护,且体外循环和主动脉阻断时间可能更短。